Euronews is no longer accessible on Internet Explorer. This browser is not updated by Microsoft and does not support the last technical evolutions. We encourage you to use another browser, such as Edge, Safari, Google Chrome or Mozilla Firefox.

Biogen profit rises 72% on multiple sclerosis therapy sales

Biogen profit rises 72% on multiple sclerosis therapy sales
FILE PHOTO: A sign marks a Biogen facility in Cambridge, Massachusetts, U.S. January 26, 2017. REUTERS/Brian Snyder -
Brian Snyder(Reuters)
Euronews logo
Text size Aa Aa

(Reuters) – Biogen Inc <BIIB.O> posted a 72% rise in quarterly profit and lifted its 2019 earnings forecast on Tuesday, boosted by higher sales of its top-selling multiple sclerosis therapy Tecfidera.

Shares of the company rose 5.4% to $244.99 before the bell, as the U.S. biotechnology company raised its 2019 adjusted earnings forecast to between $31.50 and $32.30 per share from the prior range of $28 to $29.

Analysts were expecting earnings of $29.70 per share, according to IBES data from Refinitiv.

Tecfidera brought in $1.15 billion (£924.21 million) in second-quarter sales, beating estimates of $1.05 billion.

On the other hand, sales of spinal muscular atrophy treatment Spinraza, the company’s most closely watched growth driver, came in at $488 million, missing estimates of $535.1 million.

Net income attributable to the company rose to $1.49 billion, or $7.85 per share, in the quarter ended June 30, from $866.6 million, or $4.18 per share, a year earlier. (

Excluding items, Biogen earned $9.15 per share.

Total revenue rose to $3.62 billion from $3.36 billion.

(Reporting by Saumya Sibi Joseph and Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)

euronews provides breaking news articles from reuters as a service to its readers, but does not edit the articles it publishes. Articles appear on for a limited time.